Molecular biology and pathogenicity of human and animal parvoviruses
- PMID: 2171487
Molecular biology and pathogenicity of human and animal parvoviruses
Abstract
The so-called autonomous parvoviruses comprise a wide spectrum of viral agents with quite similar physicochemical and biological properties. Characteristically, they are small, naked, and extraordinarily stable particles made up of only 2-4 structural proteins and a genome of linear, single-stranded DNA consisting of 4500-5600 nts. For replication they depend on cellular helper functions which become available at distinct stages during cellular differentiation (developmentally-dependent functions) and transiently during the phase of DNA synthesis in the mitotic cycle (cell cycle-dependent function(s)) of a susceptible cell. Most of the clinical syndromes induced by parvoviruses therefore can be related to infection of mitotically active cells or tissues at different stages in the development and maturation of the host organism. This view of parvovirus pathogenicity holds true for all animal parvoviruses as well as for the human parvovirus B19.
Similar articles
-
Variants of B19.Dev Biol (Basel). 2004;118:71-7. Dev Biol (Basel). 2004. PMID: 15645675 Review.
-
Identification of a novel simian parvovirus in cynomolgus monkeys with severe anemia. A paradigm of human B19 parvovirus infection.J Clin Invest. 1994 Apr;93(4):1571-6. doi: 10.1172/JCI117136. J Clin Invest. 1994. PMID: 8163659 Free PMC article.
-
Comparisons of feline panleukopenia virus, canine parvovirus, raccoon parvovirus, and mink enteritis virus and their pathogenicity for mink and ferrets.Am J Vet Res. 1987 Oct;48(10):1429-35. Am J Vet Res. 1987. PMID: 2823648
-
Hematologic and hematopoietic consequences of B19 parvovirus infection.Semin Hematol. 1988 Apr;25(2):159-72. Semin Hematol. 1988. PMID: 2838911 Review.
-
Serologic and molecular detection of human Parvovirus B19 infection.Clin Chim Acta. 2006 Oct;372(1-2):14-23. doi: 10.1016/j.cca.2006.04.018. Epub 2006 Jun 9. Clin Chim Acta. 2006. PMID: 16765338 Review.
Cited by
-
Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1.Front Oncol. 2014 May 1;4:92. doi: 10.3389/fonc.2014.00092. eCollection 2014. Front Oncol. 2014. PMID: 24822170 Free PMC article. Review.
-
TIPICO X: report of the 10th interactive infectious disease workshop on infectious diseases and vaccines.Hum Vaccin Immunother. 2021 Mar 4;17(3):759-772. doi: 10.1080/21645515.2020.1788301. Epub 2020 Aug 5. Hum Vaccin Immunother. 2021. PMID: 32755474 Free PMC article.
-
Ubiquitin-independent proteasomal degradation during oncogenic viral infections.Biochim Biophys Acta. 2011 Dec;1816(2):147-57. doi: 10.1016/j.bbcan.2011.05.005. Epub 2011 Jun 6. Biochim Biophys Acta. 2011. PMID: 21664948 Free PMC article. Review.